DOCSLIB.ORG

Etomidate in the Management of Hypercortisolaemia in Cushing's

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Etomidate in the Management of Hypercortisolaemia in Cushing's European Journal of Endocrinology (2012) 167 137–143 ISSN 0804-4643 REVIEW THERAPY IN ENDOCRINE DISEASE Etomidate in the management of hypercortisolaemia in Cushing’s syndrome: a review Veronica A Preda1,2, Jonathan Sen1, Niki Karavitaki1 and Ashley B Grossman1 1Department of Endocrinology, Oxford Centre for Diabetes Endocrine and Metabolism, Churchill Hospital, Oxford OX3 7LJ, UK and 2University of Sydney, Royal North Shore Hospital, St Leonards Sydney NSW 2065, Australia (Correspondence should be addressed to A B Grossman; Email: [email protected]) Abstract This review addresses the practical usage of intravenous etomidate as a medical therapy in Cushing’s syndrome. We reviewed the relevant literature, using search terms ‘etomidate’, ‘Cushing’s syndrome’, ‘adrenocortical hyperfunction’, ‘drug therapy’ and ‘hypercortisolaemia’ in a series of public databases. There is a paucity of large randomised controlled trials, and data on its use rely only on small series, case study reports and international consensus guideline recommendations. Based on these, etomidate is an effective parenteral medication for the management of endogenous hypercortisolaemia, particularly in cases with significant biochemical disturbance, sepsis and other serious complications such as severe psychosis, as well as in preoperative instability. We suggest treatment protocols for the safe and effective use of etomidate in Cushing’s syndrome. European Journal of Endocrinology 167 137–143 Introduction appropriate laparoscopic surgical expertise exists. Earlier planned surgical intervention may be a means Endogenous Cushing’s syndrome results from excessive of resolving hypercortisolaemia, although even with glucocorticoid production with a failure of the normal modern techniques preoperative lowering of the negative feedback effect on the hypothalamo-pituitary– hypercortisolaemia may be important. However, there adrenal axis. It is traditionally divided into ACTH- is still a widespread requirement for medical therapy. dependent and ACTH-independent Cushing’s syn- In the first instance, severe biochemical disturbance drome. In the majority of cases, it is caused by an (e.g. hypokalaemia), immunosuppression and/or men- adenoma in the pituitary gland secreting ACTH tal instability may need immediate and life-saving hormone (Cushing’s disease), more rarely due to cortisol-lowering therapy, while following radiotherapy, ACTH secretion by an ectopic source; of the adrenal medical therapy may be necessary whilst waiting for the causes, these are usually adrenal adenomas or carci- treatment to become effective. In some cases, surgical nomas, with a small group due to bilateral adrenal cure is impossible and management with drugs able to hyperplasia (1). Detailed biochemical and imaging lower cortisol may be needed in the short term or even paradigms have been designed to diagnose the presence in the long term (1, 3). of Cushing’s syndrome and to differentially identify The medical therapy of hypercortisolaemia in Cush- ACTH dependence or independence and the precise ing’s syndrome is predominantly based on the inhi- pathology. If untreated, there is significant morbidity bition of adrenal steroidogenesis at one or more and potential mortality related to life-threatening enzymatic sites, or alternatively by antagonism of the infections, diabetes mellitus, hypertension and an glucocorticoid receptor or the suppression of ACTH. increased risk associated with surgery. Oral therapy with ketoconazole and metyrapone are the For Cushing’s disease, surgical removal of the most frequent steroidogenic enzyme inhibitors cur- pituitary tumour is the usual first-line therapy, with rently in use, but these agents are not always well radiotherapy reserved for surgical failure, or occasion- tolerated. Ketoconazole is associated with disturbances ally bilateral adrenalectomy. Laparoscopic adrenalect- of hepatic function, while metyrapone may cause omy is highly effective in the ectopic ACTH syndrome nausea independent of its cortisol-lowering activity (2) and occasionally in Cushing’s disease, but its use and thus large doses cannot be taken, and accumu- may cause unnecessary or inappropriate delay. Patients lation of androgenic precursors may be problematic (4). should be referred in a timely fashion to a facility where Occasional patients may need to be treated with the q 2012 European Society of Endocrinology DOI: 10.1530/EJE-12-0274 Online version via www.eje-online.org Downloaded from Bioscientifica.com at 10/01/2021 07:49:19PM via free access 138 V A Preda and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 167 glucocorticoid receptor antagonist mifepristone, or a aldosterone blockade and anti-tumorigenesis for meta- minority of patients with Cushing’s disease may have static adrenocortical tumours. Post-translational work their excess cortisol normalised with pasireotide. is underway to manufacture synthetic similar Subcutaneous pasireotide is a new targeted pituitary compounds to etomidate with high potency inhibition therapy, a somatostatin analogue that binds to the of the steroid pathway and weak interactions with somatostatin receptors and with particular high affinity g-aminobutyric acid type A receptors in order to for somatostatin receptor subtype 5. It normalised harness its therapeutic benefits in treating hypercorti- glucocorticoid output in around 20–25% of patients solism and to minimise its anaesthetic properties (8). in a recent study, although its major side effects, hyperglycaemia and diabetes mellitus, occurred in 73% of patients (5). However, in patients with severe Methodology hypercortisolaemia unable or unwilling to tolerate oral therapy, bilateral adrenalectomy may be necessary Publications were identified by means of a systematic (4, 6). Surgical risk may be significantly reduced if literature search in the period of January 1946 to April cortisol concentrations are normalised preoperatively 2012 using the Medline, EMBASE, Cochrane and (12). Thus, the use of a parenteral hypocortisolaemic Scopus databases, limited to English language publi- agent may be essential before or during adrenalectomy cations. Other studies were identified from the bibli- in patients with severe life-threatening hypercortisolae- ography of short-listed articles. The search criteria used mia. Intravenous etomidate has a role in this setting. in the Medical Subject Headings (MeSH) are as follows: ‘etomidate, Cushing’s syndrome, hypercortisolaemia, adrenocortical hyperfunction and drug therapy’. Etomidate Supplementary references for guidelines were identified via Google Scholar. An initial review of all titles and Etomidate and ketoconazole are members of the abstracts was performed for relevance. If deemed imidazole family. Etomidate is a carboxylated imidazole appropriate for further review, access to the full article synthesised in 1964 and introduced into use in 1972. was obtained. Eighteen key clinical references, most of It was developed as an intravenous hypnotic non- which were case reports for the primary therapeutic use barbiturate induction anaesthetic agent (7) and has a of etomidate in hypercortisolism, were identified. plasma half-life of 3–5 h. The anaesthetic effects of etomidate in the CNS are thought to be via activation of g-aminobutyric acid type A receptors (8). Etomidate Clinical experience was popular for its reputation in cardiovascular stability, with little change in blood pressure and heart Ga¨rtner et al. (18) used the therapeutic effect of sedative rate, as well as lack of histamine release, but was noted doses of 15–30 mg/h etomidate in a 53-year male to result in increased mortality in critically unwell patient with an ectopic ACTH-producing tumour and patients (9): this was later shown to be associated with untreatable psychosis. They were the first to demon- low serum cortisol levels resulting in hypoadrenalism strate the beneficial effect of etomidate on hyper- (10). However, a recent meta-analysis was unable to cortisolism for clinical benefit over a 14-day infusion conclude that there was an increase in mortality in with improvement in the patient’s hypertension and patients who were given etomidate as a single dose in hypokalaemia associated with a fall in cortisol levels. rapid sequence induction anaesthesia (11): the debate Engelhardt et al. (19) demonstrated the cortisol- on the usage of etomidate in the anaesthetic literature lowering effect of non-sedating etomidate in three continues. Etomidate inhibits the mitochondrial cyto- normal volunteers in 1986. Allolio et al. (20) in 1988 chrome p450-dependent adrenal enzyme 11b- were the first to demonstrate that a 32-h infusion of hydroxylase that catalyses the production of cortisol low-dose 2.5 mg/h ethyl alcohol etomidate could inhibit from deoxycortisol and is 95% homologous to the cortisol secretion in patients with hypercortisolaemia aldolase enzyme in the pathway to aldosterone within 11–24 h. They were able to demonstrate that synthesis, lowering serum cortisol levels within 12 h low plasma doses achieved adrenocortical blockade (12, 13, 14, 15). On this basis, it was suggested that distinct from the sedative potential used in anaesthesia, etomidate could be a useful therapy for severe which was typically at a dose of an initial induction hypercortisolaemia in patients intolerant of or unable anaesthetic bolus of 0.03 mg/kg followed by a continu- to take oral medication. At higher doses, etomidate ous infusion of 0.3 mg/kg per h to maintain sedation. blocks side chain cleavage enzyme.
Load more

Recommended publications
  • Analgesia and Sedation in Hospitalized Children
    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical
    THE CARDIORESPIRATORY AND ANESTHETIC EFFECTS OF CLINICAL AND SUPRA CLINICAL DOSES OF ALF AXALONE IN CYCLODEXTRAN IN CATS AND DOGS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Laura L. Nelson, B.S., D.V.M. * * * * * The Ohio State University 2007 Dissertation Committee: Professor Jonathan Dyce, Adviser Professor William W. Muir III Professor Shane Bateman If I have seen further, it is by standing on the shoulders of giants. lmac Ne1vton (1642-1727) Copyright by Laura L. Nelson 2007 11 ABSTRACT The anesthetic properties of steroid hormones were first identified in 1941, leading to the development of neurosteroids as clinical anesthetics. CT-1341 was developed in the early 1970’s, featuring a combination of two neurosteroids (alfaxalone and alphadolone) solubilized in Cremophor EL®, a polyethylated castor oil derivative that allows hydrophobic compounds to be carried in aqueous solution as micelles. Though also possessing anesthetic properties, alphadolone was included principally to improve the solubility of alfaxalone. CT-1341, marketed as Althesin® and Saffan®, was characterized by smooth anesthetic induction and recovery in many species, a wide therapeutic range, and no cumulative effects with repeated administration. Its cardiorespiratory effects in humans and cats were generally mild. However, it induced severe hypersensitivity reactions in dogs, with similar reactions occasionally occurring in cats and humans. The hypersensitivity reactions associated with this formulation were linked to Cremophor EL®, leading to the discontinuation of Althesin® and some other Cremophor®-containing anesthetics. More recently, alternate vehicles for hydrophobic drugs have been developed, including cyclodextrins.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • IV Induction Agents
    Intravenous drugs used for the induction of anaesthesia Dr Tom Lupton, Specialist Registrar in Anaesthesia Dr Oliver Pratt, Consultant Anaesthetist Salford Royal Hospitals NHS Foundation Trust, Salford, UK Key questions This tutorial reviews the basic pharmacology of common intravenous (IV) anaesthetic drugs. By the end of the tutorial, you should be able to decide on the most appropriate drug to use in the situations below and for what reason: 1. A patient with intestinal obstruction requires an emergency laparotomy. 2. A patient with a history of throat cancer, showing marked stridor and signs of respiratory distress, requires a tracheostomy. 3. A patient requiring a burn dressing change. 4. A patient with a history of heart failure requires a general anaesthetic. 5. A dehydrated hypovolaemic patient requires an emergency general anaesthetic. 6. A patient with porphyria comes for an inguinal hernia repair and is requesting a general anaesthetic. 7. A patient requires sedation on the intensive care unit. 8. Anaesthesia in the prehospital environment. What are IV induction drugs? These are drugs that, when given intravenously in an appropriate dose, cause a rapid loss of consciousness. This is often described as occurring within “one arm-brain circulation time” that is simply the time taken for the drug to travel from the site of injection (usually the arm) to the brain, where they have their effect. They are used: • To induce anaesthesia prior to other drugs being given to maintain anaesthesia. • As the sole drug for short procedures. • To maintain anaesthesia for longer procedures by intravenous infusion. • To provide sedation. The concept of intravenous anaesthesia was born in 1932, when Wesse and Schrapff published their report into the use of hexobarbitone, the first rapidly acting intravenous drug.
    [Show full text]
  • Safety and Efficacy of Etomidate And
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2016 Safety and efficacy of etomidate and propofol anesthesia in elderly patients undergoing gastroscopy: A double-blind randomized clinical study Qing-Tao Meng Wuhan University Chen Cao The Third Hospital of Wuhan Hui-Min Liu Wuhan University Zhong-Yuan Xia Wuhan University Wei Li Wuhan University See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Meng, Qing-Tao; Cao, Chen; Liu, Hui-Min; Xia, Zhong-Yuan; Li, Wei; Tang, Ling-Hua; Chen, Rong; Jiang, Meng; Wu, Yang; Leng, Yan; and Lee, Chris C., ,"Safety and efficacy of etomidate and propofol anesthesia in elderly patients undergoing gastroscopy: A double-blind randomized clinical study." Experimental and Therapeutic Medicine.12,3. 1515-1524. (2016). https://digitalcommons.wustl.edu/open_access_pubs/5193 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Qing-Tao Meng, Chen Cao, Hui-Min Liu, Zhong-Yuan Xia, Wei Li, Ling-Hua Tang, Rong Chen, Meng Jiang, Yang Wu, Yan Leng, and Chris C. Lee This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5193 EXPERIMENTAL AND THERAPEUTIC MEDICINE 12: 1515-1524, 2016 Safety and efficacy of etomidate and propofol anesthesia in elderly patients undergoing gastroscopy: A double‑blind randomized clinical study QING-TAO MENG1*, CHEN CAO2*, HUI-MIN LIU1*, ZHONG-YUAN XIA1, WEI LI1, LING-HUA TANG1, RONG CHEN1, MENG JIANG1, YANG WU1, YAN LENG1 and CHRIS C.
    [Show full text]
  • Anaesthetic Modulation of Ion Channel Kinetics in Bovine Chromaffin Cells
    280740062X ANAESTHETIC MODULATION OF ION CHANNEL KINETICS IN BOVINE CHROMAFFIN CELLS BY PAUL CHARLESWORTH Thesis submitted for the degree of Doctor of Philosophy to the Faculty of Science of the University of London Department of Physiology Royal Free Hospital School of Medicine Rowland Hill Street Hampstead London NW3 2PF ProQuest Number: U063786 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest U063786 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ABSTRACT The thesis describes a patch clamp study of the action of anaesthetics on the ion channels primarily responsible for initiating secretion in bovine chromaffin cells. The adrenal chromaffin cell is homologous with sympathetic post-ganglionic neurones and was chosen as a model for studying excitatory neuronal synapses. Pre- and post- synaptic events are modelled by effects on the voltage-gated calcium channels and nicotinic acetylcholine receptor channel respectively. The overall aim has been to describe anaesthetic depression of excitatory synaptic transmission at the ion channel level. Results of experiments with a representative range of anaesthetic agents are shown.
    [Show full text]
  • Etomidate Injection, USP Approximately Double That Seen in Healthy Subjects
    2585 suggest that the volume of distribution and elimination half-life of etomidate are Etomidate Injection, USP approximately double that seen in healthy subjects. 2 mg/mL (Reference: H. Van Beem, et. al., Anaesthesia 38 (Supp 38:61-62, July 1983). Rx only In clinical studies, elderly patients demonstrated decreased initial distribution DESCRIPTION volumes and total clearance of etomidate. Protein binding of etomidate to serum Etomidate Injection, USP is a sterile, nonpyrogenic solution. Each milliliter contains albumin was also significantly decreased in these individuals. etomidate, 2 mg, propylene glycol 35% v/v. The pH is 6.0 (4.0 to 7.0). Reduced plasma cortisol and aldosterone levels have been reported following It is intended for the induction of general anesthesia by intravenous injection. induction doses of etomidate. These results persist for approximately 6 to 8 hours The drug etomidate is chemically identified as (R)-(+)-ethyl-1-(1-phenylethyl)-1H- and appear to be unresponsive to ACTH stimulation. This probably represents imidazole -5-carboxylate and has the following structural formula: blockage of 11 beta-hydroxylation within the adrenal cortex. O N (References: 1. R.J. Fragen, et. al., Anesthesiology 61:652-656, 1984. 2. R.L. Wagner & P.F. White, Anesthesiology 61:647-651, 1984. 3. F.H. DeJong, et. al., CH3 CH2 O C N Clin. Endocrinology and Metabolism 59:(6):1143-1147, 1984, and three additional drafts of Metabolic Studies, all submitted to NDA 18-228 on April 1, 1985). H C CH INDICATIONS AND USAGE 3 Etomidate injection, USP is indicated by intravenous injection for the induction of general anesthesia.
    [Show full text]
  • Anesthetic Agents: General and Local Anesthetics T IMOTHY J
    Chapter 16 Anesthetic Agents: General and Local Anesthetics T IMOTHY J. MAHER Drugs Covered in This Chapter Inhaled general anesthetics • Propofol • Levobupivacaine • Ether • Fospropofol • Lidocaine • Halothane • Thiopental • Prilocaine • Desflurane Local anesthetics • Procaine • Ropivacaine • Enflurane • Articaine • Tetracaine • Isoflurane • Benzocaine • Methoxyflurane • Bupivacaine • Sevoflurane • Chloroprocaine • Nitrous oxide • Cocaine Intravenous general anesthetics • Dibucaine • Etomidate • Dyclonine • Ketamine • Mepivacaine Abbreviations BTX, batrachotoxin GABA, g-aminobutyric acid NO, nitric oxide CNS, central nervous system HBr, hydrobromic acid NMDA, N-methyl-D-aspartate COCl2, phosgene HCl, hydrochloric acid PABA, p-aminobenzoic acid EEG, electroencephalograph MAC, minimum alveolar concentration PCP, phencyclidine EMLA, Eutectic Mixture of a Local Na/K-ATPase, sodium-potassium STX, saxitoxin Anesthetic adenosine triphosphatase TTX, tetrodotoxin 508 LLemke_Chap16.inddemke_Chap16.indd 550808 112/9/20112/9/2011 44:14:08:14:08 AAMM CHAPTER 16 / ANESTHETIC AGENTS: GENERAL AND LOCAL ANESTHETICS 509 SCENARIO Paul Arpino, R.Ph. CDL is a 70-year-old obese man scheduled for carpal tunnel sur- During the preoperative assessment before the scheduled day of gery. A review of his medical file indicates a history of obstruc- surgery, the team discovers that CDL has an undefined allergy tive sleep apnea and benign prostatic hypertrophy (BPH). CDL to procaine (Novocain) and that he experienced severe blistering sleeps with a continuous positive pressure airway device and his after a dental procedure many years ago and was told he cannot BPH is treated with tamsulosin, 0.4 mg daily. Given that patients receive “drugs like Novocain again.” with sleep apnea are at high risk for respiratory depression, the clinical team decides that a peripheral nerve block would be a (The reader is directed to the clinical solution and chemical analy- better alternative to both neuraxial and general anesthesia.
    [Show full text]
  • Dexmedetomidine Combined with Etomidate Or Emulsified Isoflurane for Induction Reduced Cardiopulmonary Response in Dogs
    RESEARCH ARTICLE Dexmedetomidine combined with etomidate or emulsified isoflurane for induction reduced cardiopulmonary response in dogs Chao LiuID, Tingting LinID, Zhenlei Zhou* College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu, China * [email protected] a1111111111 Abstract a1111111111 To investigate the effects of etomidate, emulsified isoflurane, and their combination with a1111111111 a1111111111 dexmedetomidine on physiological parameters, electrocardiogram (ECG) results, and the a1111111111 quality of induction and recovery during isoflurane maintenance anaesthesia. 5 mixed- breed dogs received each of four treatments: etomidate (E group); emulsified isoflurane (EI group); both dexmedetomidine and etomidate (DE group); or both dexmedetomidine and emulsified isoflurane (DEI group). All drugs were IV injection administered for induction, fol- OPEN ACCESS lowed by 1.5 MAC (minimal alveolar concentration) of isoflurane to maintain anaesthesia. Rectal temperature (RT), respiratory rate (RR), heart rate (HR), mean arterial pressure Citation: Liu C, Lin T, Zhou Z (2018) Dexmedetomidine combined with etomidate or (MAP), and ECG were measured at baseline, 0, 5, 10, 20, 40, and 60 minutes after intuba- emulsified isoflurane for induction reduced tion. The quality of induction and recovery was evaluated for all dogs. All the anaesthetic cardiopulmonary response in dogs. PLoS ONE 13 procedures provided good conditions for induction of anaesthesia. The quality of induction (12): e0208625. https://doi.org/10.1371/journal. pone.0208625 and recovery in the E group was worse than other groups. The decrease of RR in the E and DE groups was stronger than that in the EI and DEI groups. The dogs in the E group had the Editor: Francesco Staffieri, University of Bari, ITALY most significant prolongation of the Q-T interval and changes in the S-T segment.
    [Show full text]
  • Clinical and Molecular Pharmacology of Etomidate
    REVIEW ARTICLE David S. Warner, M.D., Editor Clinical and Molecular Pharmacology of Etomidate Stuart A. Forman, M.D., Ph.D.* ABSTRACT TOMIDATE [R-1-(1-ethylphenyl)imidazole-5-ethyl E ester] (fig. 1) is a unique drug used for induction of general anesthesia and sedation. The first report on etomi- This review focuses on the unique clinical and molecular date was published in 1965 as one of several dozen aryl alkyl pharmacologic features of etomidate. Among general anes- imidazole-5-carboxylate esters1 synthesized by Janssen Phar- thesia induction drugs, etomidate is the only imidazole, and maceuticals (a division of Ortho-McNeil-Jannsen Pharma- it has the most favorable therapeutic index for single-bolus ceuticals, Titusville, NJ). Initially developed as antifungal administration. It also produces a unique toxicity among agents, the potent hypnotic activity of several compounds anesthetic drugs: inhibition of adrenal steroid synthesis that was observed during animal testing; and several com- far outlasts its hypnotic action and that may reduce survival pounds, including etomidate, appeared significantly safer of critically ill patients. The major molecular targets mediat- than barbiturates. ing anesthetic effects of etomidate in the central nervous Etomidate contains a chiral carbon (fig. 1). Initial studies ␥ system are specific -aminobutyric acid type A receptor sub- of racemic etomidate in rats demonstrated lethality at ap- types. Amino acids forming etomidate binding sites have proximately 12 times its effective hypnotic dose (median been identified in transmembrane domains of these proteins. lethal dose/ED50, approximately 12) compared with barbi- Etomidate binding site structure models for the main en- turates with median lethal dose/ED50 ratios (therapeutic in- zyme mediating etomidate adrenotoxicity have also been de- dexes) of 3–5.1 Subsequent studies2,3 found that the isolated veloped.
    [Show full text]
  • Rapid Sequence Intubation: Medications, Dosages, and Recommendations
    Rapid Sequence Intubation: Medications, dosages, and recommendations Timeline of Rapid Sequence Intubation S Zero Minus Zero Minus Zero Minus Zero Zero plus 20- Zero plus 10 Minutes 5 Minutes 3 Minutes 30 seconds 45 seconds 7. Post- intubation management 1. Preparation 2. Preoxygenation 3. 4. Paralysis/ 5. Positioning 6. Placement Pretreatment Induction with proof 1. Preparation – Assemble all necessary equipment, drug, etc. 2. Preoxygenation – Replace the nitrogen in the patient’s functional reserve with oxygen – “nitrogen wash out – oxygen wash in” 3. Pretreatment – Ancillary medications are administered to mitigate the adverse physiologic consequences of intubation 4. Paralysis with induction – Administer sedative induction agent via IV push, followed immediately by administration of paralytic via IV push 5. Positioning – Position patient for optimal laryngoscopy; Sellick’s maneuver, if desired, is applied now 6. Placement with proof – Assess mandible for flaccidity; perform intubation, confirm placement 7. Post-intubation management – Long-term sedation/analgesia/paralysis as indicated Pre-treatment – agents should be given 3 minutes prior to intubation (can be given in any order) Drug Dose Indication Other notes Lidocaine 100 mg Head injury, traumatic Lidocaine will help brain injury, unknown protect the patient mechanism of injury, from increases in elevated ICP intracranial pressure caused by intubation Fentanyl 2-3 mcg/kg Elevated ICP, Fentanyl helps decrease cardiovascular disease catecholamine (ischemic coronary discharge secondary to disease, aneurismal intubation, thus disease, great vessel decreasing the risks rupture or dissection, associated from BP intracranial increases in pts with CV hemorrhage) disease, aortic dissections, etc. Be careful if the patient is already hypotensive Rocuronium 0.1 mg/kg Head injury, traumatic Defasciculation no (defasciculation) (e.g., 7 mg in a 70 kg pt) brain injury, unknown longer routinely mechanism of injury, recommended.
    [Show full text]